ArticleObstetrics and gynecology international2026
Trends in Use of Antiseizure Medicines in Women With Epilepsy in Pregnancy During 2018-2023 in an Irish Maternity Hospital: A Cohort Study.
Article in Obstetrics and gynecology international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to describe and explore the trends of antiseizure medicine (ASM) use in women with epilepsy (WWE) in pregnancy over a 6-year period. Methods: This observational cohort study used routinely collected electronic health record (EHR) data from a large maternity hospital in Dublin, Ireland, with > 9000 births annually. WWE attending during pregnancy between 2018 and 2023 were included. Descriptive statistics and linear and negative binomial regression models were used to assess temporal trends. Outcomes included individual ASM exposure, ASM safety category ('Known safest', 'Uncertain risk' and 'Higher risk') and temporal trends in ASM use. Results: There were 286 ASM-exposed pregnancies in WWE. The overall proportion of ASM-exposed pregnancies in WWE ranged between 87.7% and 95.7% per year. Trends for most ASMs and overall safety categories did not change significantly or had insufficient data to assess trends over time. Levetiracetam (60.1%) and lamotrigine (31.5%) were most frequently used overall. Zonisamide use decreased significantly (-0.395, Conclusions: In this single-centre EHR cohort, trends in use of ASMs in WWE appeared relatively stable, although analyses of less commonly used ASMs were limited by very small numbers. ASMs with safer pregnancy profile were most frequently used in WWE in pregnancy. Additional data are needed to further assess trends and outcomes and to determine the place of newer generation ASMs in WWE in pregnancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.